Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep;10(9):1311-1318.
doi: 10.1097/JTO.0000000000000627.

Early Detection of Lung Cancer with Meso Tetra (4-Carboxyphenyl) Porphyrin-Labeled Sputum

Affiliations

Early Detection of Lung Cancer with Meso Tetra (4-Carboxyphenyl) Porphyrin-Labeled Sputum

Lara Patriquin et al. J Thorac Oncol. 2015 Sep.

Abstract

Introduction: Early detection of lung cancer in high-risk individuals reduces mortality. Low-dose spiral computed tomography (LDCT) is the current standard but suffers from an exceedingly high false-positive rate (>96%) leading to unnecessary and potentially dangerous procedures. We, therefore, set out to develop a simple, noninvasive, and quantitative assay to detect lung cancer.

Methods: This proof-of-concept study evaluated the sensitivity/specificity of the CyPath Early Lung Cancer Detection Assay to correctly classify LDCT-confirmed cohorts of high-risk control (n = 102) and cancer (n = 26) subjects. Fluorescence intensity parameters of red fluorescent cells (RFCs) from tetra (4-carboxyphenyl) porphyrin (TCPP)-labeled lung sputum samples and subjects' baseline characteristics were assessed for their predictive power by multivariable logistic regression. A receiver operating characteristic curve was constructed to evaluate the sensitivity/specificity of the CyPath assay.

Results: RFCs were detectable in cancer subjects more often than in high-risk ones (p = 0.015), and their characteristics differed between cohorts. Two independent predictors of cancer were the mean of RFC average fluorescence intensity/area per subject (p < 0.001) and years smoked (p = 0.003). The CyPath-based classifier had an overall accuracy of 81% in the test population; false-positive rate of 40% and negative predictive value of 83%.

Conclusions: The tetra (4-carboxyphenyl) porphyrin -based CyPath assay correctly classified study participants into cancer or high-risk cohorts with considerable accuracy. Optimizing sputum collection, sample reading, and refining the classifier should improve sensitivity and specificity. The CyPath assay thus has the potential to complement LDCT screening or serve as a stand-alone approach for early lung cancer detection.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Subject enrollment and participation.
FIGURE 2
FIGURE 2
Characteristics of CyPath-stained cells. A, The intense red color of red fluorescent cells (RFCs) indicates uptake of tetra (4-carboxyphenyl) porphyrin (TCPP) and demonstrates a characteristic fluorescence when viewed after exposure to blue light (of a mercury vapor light source) through an Olympus U-MWIB3 filter. This is in contrast to surrounding background cells (A, background) which do not take up TCPP and appear dull when viewed under these conditions. B, Spectral emission profiles for the cells identified by arrowheads in A. C, Average fluorescence intensity (FI) versus log10 area of cells chosen at random (green, grey, blue) and of RFCs from high-risk (orange) and cancer (black) cohorts. The distinction between large and small was based on the k-means (k = 2) partitioning of the log10 area of background cells.
FIGURE 3
FIGURE 3
Receiver operating characteristic curve for the CyPath assay classifier. The accuracy of classifying each participant as cancer/no cancer was tabulated as the probability cutoff for the predictive model was varied. The red curve shows the changes in specificity and sensitivity for the CyPath assay at the different probability thresholds. The black line indicates the expected result if subjects were assigned randomly.

References

    1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2011. Bethesda, MD: National Cancer Institute; Available at: http://seer.cancer.gov/csr/1975_2011 (based on November 2013 SEER data submission, posted to the SEER web site, April 2014. Available at: http://seer.cancer.gov/statfacts/html/lungb.html). Accessed June 2014.
    1. Goldberg SW, Mulshine JL, Hagstrom D, Pyenson BS. An actuarial approach to comparing early stage and late stage lung cancer mortality and survival. Popul Health Manag. 2010;13:33–46. - PubMed
    1. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409. - PMC - PubMed
    1. Church TR, Black WC, Aberle DR, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368:1980–1991. - PMC - PubMed
    1. Moyer VA. U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160:330–338. - PubMed

Publication types